نتایج جستجو برای: degarelix
تعداد نتایج: 125 فیلتر نتایج به سال:
Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer
It is estimated that around 55-60% of men with prostate cancer will develop metastatic disease, most commonly involving bone. The initial treatment for metastatic disease is hormonal ablation, either with surgery (bilateral orchidectomy) or medically with gonadotrophin releasing hormone analogues such as goserelin, leuprorelin or triptorelin. A luteinising hormone-releasing hormone (LHRH) antag...
AIM We combined anti-androgen therapy with radiotherapy in a first-line setting for metastatic prostate cancer aiming to cause maximal cancer-cell death to delay the emergence of castration-resistant disease. MATERIALS AND METHODS In this non-randomized retrospective series of 46 patients, the initial median prostate-specific antigen (PSA) was 98.5 μg/l (range=6.7-15,500), median Gleason scor...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید